Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Traws Pharma (TRAW) Capital Expenditures (2019)

Traws Pharma (TRAW) has disclosed Capital Expenditures for 4 consecutive years, with -$1000.0 as the latest value for Q4 2019.

For Q4 2019, Capital Expenditures changed N/A year-over-year to -$1000.0; the TTM value through Dec 2023 reached -$1000.0, changed N/A, while the annual FY2025 figure was $2.6 million, 29.14% down from the prior year.
Capital Expenditures hit -$1000.0 in Q4 2019 for Traws Pharma, down from $6000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at -$1000.0 in Q4 2019 and bottomed at -$1000.0 in Q4 2019.